MeiraGTx Regains Global Rights to bota-vec for XLRP Gene Therapy from J&J and Proceeds with Phase 3 Follow-up Study
MeiraGTx Seeks a Turnaround by Reacquiring Rights
MeiraGTx has reacquired global rights to botaretigene sparoparvovec (bota-vec), a gene therapy candidate for X-linked Retinitis Pigmentosa (XLRP), from Johnson & Johnson's (J&J) subsidiary, Janssen, for a total of $75 million. This move is seen as a strategic decision by the original developer to pursue independent commercialization, believing in the potential for success, amidst the trend of large corporations streamlining their pipelines. MeiraGTx already possesses its own manufacturing facilities, allowing it to maintain a stable commercial manufacturing process even after the partnership ends.
Behind the Phase 3 Trial and the Value of Secondary Endpoints
bota-vec faced a setback when the topline results of the Phase 3 LUMEOS study, released in May 2025, did not meet the primary endpoint of vision-guided mobility. However, it demonstrated clinically meaningful improvements in key secondary endpoints such as retinal sensitivity and visual acuity in low-light conditions. Consequently, MeiraGTx is conducting a long-term follow-up Phase 3 trial (NCT04794101) to accumulate long-term safety and efficacy data, providing evidence to persuade regulatory agencies.
Exclusive Commercialization Opportunity in the Rare Disease Market
The global market for Retinitis Pigmentosa (RP) is currently estimated at $10 billion to $15 billion, and XLRP is the most severe form of this rare ophthalmic disease, with no approved treatments available. Based on the accumulated clinical data, MeiraGTx plans to pursue regulatory approvals from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) with the goal of a global commercial launch in 2027. If approved, it will have the opportunity to secure a first-in-class position in this indication and dominate the market.
Fierce Competition and Portfolio Diversification
Of course, the competition for market leadership is intense, with Beacon Therapeutics' competing drug, AGTC-501, receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and accelerating subsequent clinical trials. For MeiraGTx, overcoming the risk of clinical failure and obtaining regulatory approval faster than its competitors will be the key factor determining the success of its return on investment (ROI). Industry analysts believe that MeiraGTx has secured long-term growth potential through this reacquisition, but in the short term, it will need to raise additional capital and supplement and verify clinical data to overcome regulatory hurdles.
MeiraGTx's reacquisition of global rights to bota-vec from J&J for up to $75 million represents a high-risk, high-reward strategy to acquire an asset that failed to meet the primary endpoint in a Phase 3 trial at a lower cost and pursue independent commercialization. In the short term, the goal is to obtain regulatory approval by 2027 based on data from the secondary endpoint of improved retinal sensitivity, which, if successful, would allow it to secure a leading position as the first XLRP treatment. In the medium to long term, this provides an opportunity to establish a solid revenue pipeline within the overall $10 billion to $15 billion Retinitis Pigmentosa market and maximize corporate value. However, the commercialization race against Beacon Therapeutics, which has received FDA RMAT designation and is rapidly progressing with Phase 2/3 trials for AGTC-501, is an unavoidable threat. Therefore, the long-term safety data from the Phase 3 follow-up study (NCT04794101) and the approval of the marketing application will be the key determinants of MeiraGTx's future investment value.
Source: ClinicalTrials.gov (api_ct)